VIR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Vir Biotechnology Inc. (VIR) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong positive catalysts, including analyst upgrades, a promising oncology pipeline, and significant growth potential. Despite some short-term volatility and hedge fund selling, the long-term outlook is favorable.
The technical indicators are moderately bullish. The MACD is positive and contracting, indicating upward momentum. The RSI is neutral at 62.539, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading above its pivot level of 9.128, with resistance levels at 10.534 and 11.402, suggesting potential upside.
Multiple analyst upgrades with raised price targets (ranging from $17 to $
and strong buy/outperform ratings.
Promising Phase 1 data for VIR-5500 in oncology, positioning it as a leader in PSMA-targeted therapies.
Astellas partnership with $335M upfront payments and profit-sharing agreements.
Revenue growth of 417.78% YoY in Q4 2025, indicating strong top-line performance.
Hedge funds are selling, with a 3690.48% increase in selling activity last quarter.
Net income and EPS have declined significantly YoY (-58.96% and -59.21%, respectively), indicating profitability challenges.
In Q4 2025, revenue surged by 417.78% YoY to $64.07M, showcasing strong growth. However, net income dropped by 58.96% YoY to -$42.92M, and EPS fell by 59.21% YoY to -$0.31, reflecting ongoing profitability challenges. Gross margin improved to 99.96%, up 5.81% YoY, indicating operational efficiency.
Analysts are overwhelmingly positive on VIR, with multiple upgrades and raised price targets. Highlights include H.C. Wainwright's target of $20, Barclays' target of $30, and Raymond James' strong buy rating with a $19 target. Analysts cite the Astellas partnership, promising oncology data, and progress in the hepatitis D program as key drivers of the stock's potential.
